Related Experiment Video
Updated: Jul 13, 2025
12:08
Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
18.6K
Not one, but many: developing a multi-indication pricing model for medicines in Belgium.
Ingrid Maes1, Eline Kok1, Pieter-Jan De Torck1
1Inovigate, Wilrijk, Belgium.
Frontiers in Pharmacology
|October 16, 2023
Summary
Belgian stakeholders developed a new pricing model for multi-indication medicines, setting a single launch price adjusted by real-world performance across indications. This approach aims to improve market access for complex therapies.
Area of Science:
- Health economics
- Pharmaceutical policy
- Market access
Background:
- Current pricing models inadequately address multi-indication medicines.
- Market access for drugs with multiple uses requires innovative reimbursement strategies.
Purpose of the Study:
- To co-create a multi-indication pricing model and procedural pathway with Belgian stakeholders.
- To identify implementation conditions and illustrate the model with a case study.
Main Methods:
- Literature review of international multi-indication pricing models.
- Semi-structured interviews with 21 diverse Belgian stakeholders.
- Multi-stakeholder roundtable to reach consensus on a preferred model.
Main Results:
- Four international models were identified, varying in pricing strategy and dynamism.
- Belgian stakeholders favored a single, volume- and value-weighted average price at launch.
- This price is dynamically adjusted based on real-world evidence for each indication over time.
Conclusions:
- The preferred model allows medicine prices to evolve based on performance across indications.
- Implementation requires a robust legal framework, data infrastructure, and stakeholder collaboration.
- While administratively intensive, this model enhances market access for multi-indication therapies.
Related Concept Videos
01:06Three-Compartment Open Model
248
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
248
01:12Analysis of Population Pharmacokinetic Data
268
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
268
01:09One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
291
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
291
01:14Multicompartment Models: Overview
158
Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
158
01:20Pharmacokinetic Models: Overview
737
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
737
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
223
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
223